Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-22
2011-03-22
Szperka, Michael (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C424S130100
Reexamination Certificate
active
07910707
ABSTRACT:
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
REFERENCES:
patent: 4289690 (1981-09-01), Pestka
patent: 4341761 (1982-07-01), Ganfield
patent: 4423147 (1983-12-01), Secher
patent: 4474754 (1984-10-01), Shimizu
patent: 4514507 (1985-04-01), Secher
patent: 4824432 (1989-04-01), Skurkovich
patent: 4885166 (1989-12-01), Meyer
patent: 4902618 (1990-02-01), Berg
patent: 4973556 (1990-11-01), Bove
patent: 5055289 (1991-10-01), Frincke
patent: 5071761 (1991-12-01), Meyer et al.
patent: 5073491 (1991-12-01), Familletti
patent: 5196323 (1993-03-01), Bodo
patent: 5240864 (1993-08-01), Koga
patent: 5317089 (1994-05-01), Adolf
patent: 5503828 (1996-04-01), Testa
patent: 5516515 (1996-05-01), Vellucci
patent: 5626843 (1997-05-01), Skurkovich
patent: 5676942 (1997-10-01), Testa
patent: 5780027 (1998-07-01), Maroun
patent: 5789551 (1998-08-01), Pestka
patent: 5869293 (1999-02-01), Pestka
patent: 5888511 (1999-03-01), Skurkovich
patent: 5919453 (1999-07-01), Benoit
patent: 6001589 (1999-12-01), Pestka
patent: 6117423 (2000-09-01), Berg
patent: 6136309 (2000-10-01), Novick
patent: 6150503 (2000-11-01), Pestka
patent: 6180370 (2001-01-01), Queen et al.
patent: 6299870 (2001-10-01), Pestka
patent: 6300474 (2001-10-01), Pestka
patent: 6312924 (2001-11-01), Presnell
patent: 6333032 (2001-12-01), Skurkovich
patent: 6410697 (2002-06-01), Berg
patent: 6433145 (2002-08-01), Lafleur
patent: 6514753 (2003-02-01), Pestka
patent: 6548056 (2003-04-01), Presnell
patent: 6747131 (2004-06-01), Pestka
patent: 6827934 (2004-12-01), Co et al.
patent: 2001/0012514 (2001-08-01), Skurkovich
patent: 2002/0192748 (2002-12-01), Rastelli
patent: 2003/0044410 (2003-03-01), Skurkovich
patent: 2003/0138404 (2003-07-01), Maroun
patent: 2003/0147581 (2003-08-01), Doi
patent: 2003/0147889 (2003-08-01), Tovey
patent: 2004/0067888 (2004-04-01), Tovey
patent: 2004/0105841 (2004-06-01), Pestka
patent: 2004/0110715 (2004-06-01), Escary
patent: 2004/0126799 (2004-07-01), Escary
patent: 2004/0132139 (2004-07-01), Escary
patent: 2004/0142431 (2004-07-01), Escary
patent: 2004/0203118 (2004-10-01), Escary
patent: 1306961 (1992-09-01), None
patent: 267 392 (1990-12-01), None
patent: 276 203 (1992-04-01), None
patent: 276 204 (1992-04-01), None
patent: 231007 (1985-12-01), None
patent: 254593 (1988-03-01), None
patent: 265291 (1989-03-01), None
patent: 277087 (1990-03-01), None
patent: 279266 (1990-05-01), None
patent: 279317 (1990-05-01), None
patent: 279546 (1990-06-01), None
patent: 279547 (1990-06-01), None
patent: 279548 (1990-06-01), None
patent: 283154 (1990-10-01), None
patent: 4216200 (1993-11-01), None
patent: 0 091 543 (1983-10-01), None
patent: 0 119 476 (1984-02-01), None
patent: 0 139 676 (1984-08-01), None
patent: 0 064 063 (1985-09-01), None
patent: 0 158 420 (1985-10-01), None
patent: 0 332 084 (1989-09-01), None
patent: 0 431 950 (1991-06-01), None
patent: 0 050 129 (1992-03-01), None
patent: 1 236 800 (2002-09-01), None
patent: 2657881 (1991-08-01), None
patent: 2 111 527 (1983-07-01), None
patent: 2 160 544 (1985-12-01), None
patent: 2 195 342 (1988-04-01), None
patent: 58035122 (1983-03-01), None
patent: 58035124 (1983-03-01), None
patent: 58225028 (1983-12-01), None
patent: 61013156 (1984-06-01), None
patent: 60065000 (1985-04-01), None
patent: 61072722 (1986-04-01), None
patent: 61099828 (1986-05-01), None
patent: 61225136 (1986-10-01), None
patent: 63142000 (1988-06-01), None
patent: 4077431 (1992-03-01), None
patent: 6050971 (1994-02-01), None
patent: 8801757 (1988-09-01), None
patent: 9200051 (1992-01-01), None
patent: 1756349 (1992-08-01), None
patent: WO 82/01773 (1982-05-01), None
patent: WO 83/00693 (1983-03-01), None
patent: WO 84/03105 (1984-08-01), None
patent: WO 84/03106 (1984-08-01), None
patent: WO 93/20187 (1993-10-01), None
patent: WO 95/13539 (1995-05-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/41229 (1997-11-01), None
patent: WO 98/06431 (1998-02-01), None
patent: WO 98/28001 (1998-07-01), None
patent: WO 99/64440 (1999-12-01), None
patent: WO 99/64461 (1999-12-01), None
patent: WO 00/32223 (2000-06-01), None
patent: WO 01/54721 (2001-08-01), None
patent: WO 01/62287 (2001-08-01), None
Janeway et al. Immunobiology, 3rdEd. Garland Press, 1997, p. 3:7-3:11.
Fundamental Immunology, William E.Paul, M.D. 3rd Ed. 1993, p. 242.
Portolano et al., J. Immunology, 1993, vol. 150, p. 880-887.
Brand et al., “Antibodies Developing Against a Single Recombinant Interferon Protein May Neutralize Many Other Interferon-/141 Subtypes”J. of Interferon Research13:121-125 (1993).
Allen, G., et al., “Analysis and Purification of Human Lymphoblastoid (Namalwa) Interferon Using a Monoclonal Antibody”J. Gen. Virol.63:207-212 (1982).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”J. Mol. Biol.224:487-499 (1992).
Kontsek, P., et al., “Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha”Immunology73:8-11 (1991).
Prummer, O., et al., “Interferon-α Antidobies in Autoimmune Diseases”Journal of Interferon Research9(Suppl. 1):S67-S74 (1989).
Whittall, J.T.D., et al., “The Reaction of the Anti-Interferon-α Monoclonal Antidoby, NK2, with Different Interferons”J. Gen. Virol.65:629-633 (1984).
Alexenko et al., “Mapping of an epitope of human leukocyte alpha interferon A which is recognized by the murine monoclonal antibody NK2”Biomed Sci.2(4):403-409 (1991).
Alexenko et al., “Reconstruction of an epitope capable of binding murine monoclonal antibodies NK2 within the sequence of human leukocyte interferon alpha F by site-directed mutagenesis”Biochem Biophys Res Commun.169(3):1061-1067 (Jun. 29, 1990).
King et al., “Characterization and properties of a modified human interferon-alpha containing an additonal 18 amino acids at the N-Terminus”J. Gen. Virol.64(Pt 8):1815-1818 (Aug. 1983).
Kontsek et al., “Mapping of two immunodominant structures of human interferon alpha 2c and their role in binding to cells”Mol Immunol.28(11):1289-1297 (Nov. 1991).
Kostrov et al., “[Limited proteolysis of human leukocyte interferon-alpha2 and localization of the antigenic determinant binding the monoclonal antibodies]”Biokhimiia(Abstract only) 50(11):1859-1865 (Nov. 1985).
Morser et al., “Production and screening of cell hybrids producing a monoclonal antibody to human interferon-alpha”J. Gen. Virol.53(Pt 2):257-265 (Apr. 1981).
Protzman et al., “Immunoradiometric assay of a recombinant human alpha-2 interferon (SCH 30500)”J. Clin. Microbiol.22(4):596-599 (Oct. 1985).
Schmeisser et al., “Radioiodination of human interferon-alpha2 interferes with binding of C-terminal sepcific antibodies”J. Immunol. Methods238(1-2):81-85 (Apr. 21, 2000).
Secher et al., “A monoclonal antibody for large-scale purification of human leukocyte interferon”Nature285(5765):446-450 (Jun. 12, 1980).
Slocombre et al., “High-level expression of an interferon alpha2 cloned in phage M13mp7 and subsequent purification with a monoclonal antibody”Proc Natl Acad Science USA79(18):5455-5459 (Sep. 1982).
Anonymous, “Human Interferon Alpha Subtypes, URL : http://www.researchd.com/cytokines/i fnasubt.htm”, Diagnostic Research, Inc., (retrieved on Nov. 25, 2002).
Adolf et al., “Production of Monoclonal Antibodies to human IFN-α and Their Use for Analysis of the Antigenic Composition of Various Natural Interferon”, Journal of Cellular Physiology Supplement, 2:61-68 (1982).
A
Chuntharapai Anan
Kim Jin K.
Presta Leonard G.
Stewart Timothy
Genentech Inc.
Kim Yunsoo
Naik Paul
Szperka Michael
LandOfFree
Anti-interferon-α antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-interferon-α antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-interferon-α antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687735